Objective: Review the clinical use, efectivity and side efects in a population based cohort.

Background: Safinamide is an oral, once a day adjunctive therapy for any stage of Parkinson’s disease (PD). It is a unique molecule with a novel dual mechanism of action based on the enhancement of the dopaminergic function (through potent reversible inhibition of MAO-B and of dopamine uptake) and inhibition of the excessive release of glutamate. It lauched to the market in april 2016, aproved to be use as and adjuntive therapy to mild or moderate PD patients. It has 2 doses 50mg and 100mg , but just the higher dose inhibits the release of glutamate.

Methods: We review the clinical records of PD patients that we have presecribed safinamide as clinical practice routine. We have evaluated the subjet profiles, the concomitant medicactions, the tolerability, efectivity and drug side efects.

Results: We have observed no relevant side efects , even in those patientes elder and polymedicated. The were few discontinuations of the drug, due to lack of effectiveness percived by the patient or caregives in more advances patients. Those how are is mild or initial stages refered more symtomatic relief, and that permit use of lower dose of levodopa.No neuropsychiatric side efects have been observe in subject disgnosed previously with mild cognitive decline.

Conclusions: We can conclude that safinamide is a efective and safe add on therapy. This work point that the less afected patient could be the most benefited.

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/use-of-safinamide-a-clinical-practice-review-of-2-year-experience/